Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy

Cariprazine in Bipolar Disorder: Clinical Efficacy, Tolerability, and Place in Therapy

(2013) Leslie Citrome   ADVANCES IN THERAPY

Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability

(2013) Leslie Citrome   Expert Opinion on Drug Metabolism & Toxicology

Lurasidone in Schizophrenia: New Information About Dosage and Place in Therapy

(2012) Leslie Citrome   ADVANCES IN THERAPY

Oral Antipsychotic Update: A Brief Review of New and Investigational Agents for the Treatment of Schizophrenia

(2012) Leslie Citrome   CNS SPECTRUMS

Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia

(2012) John M. Kane et al.   JOURNAL OF CLINICAL PSYCHIATRY

Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents

(2011) István Gyertyán et al.   NEUROCHEMISTRY INTERNATIONAL

Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties

(2011) Adrian Newman-Tancredi et al.   PSYCHOPHARMACOLOGY

Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile

(2010) B. Kiss et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

P.1.e.028 Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients

(2009) S. Potkin et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

(2009) Jan Volavka et al.   EXPERT OPINION ON PHARMACOTHERAPY

P.3.c.051 Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers

(2008) M. Kapás et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY